Plain-English translation of NCT06617923 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new combination treatment for ovarian cancer patients whose tumors have a specific genetic change called an ARID1A mutation. The study combines with , a chemotherapy medication. Researchers want to see if this combination can shrink tumors and help people with cancer that has come back or isn't responding to previous treatments.
Many ovarian cancer patients eventually develop resistance to standard chemotherapy, especially platinum-based drugs. This trial exists because early evidence suggests that tumors with ARID1A mutations might respond well to this specific medication combination, offering a new hope for people whose options are running out.
You likely qualify if…
You likely don't qualify if…
You would take two oral medications daily: (80 mg) for 28 days and (20 mg) for 21 days of each cycle, in a repeated 28-day schedule. You would return to the hospital or clinic for tumor imaging scans every 8 weeks for the first three cycles, then every 12 weeks after that to see how the treatment is working. You would continue treatment until your tumor stops responding, you experience unacceptable side effects, or you decide to stop—whichever comes first.
AI-generated summary from trial data · Aug 11, 2026 · Not medical advice
United States